Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.

Kelly C, Bhuva N, Harrison M, Buckley A, Saunders M.

Eur J Cancer. 2013 Jul;49(10):2303-10. doi: 10.1016/j.ejca.2013.03.004. Epub 2013 Apr 10. Review.

PMID:
23583220
2.

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.

Ransom D, Wilson K, Fournier M, Simes RJ, Gebski V, Yip D, Tebbutt N, Karapetis CS, Ferry D, Gordon S, Price TJ.

Ann Oncol. 2014 Jan;25(1):117-21. doi: 10.1093/annonc/mdt479. Epub 2013 Dec 2.

PMID:
24299960
3.

Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.

Deboever G, Hiltrop N, Cool M, Lambrecht G.

Clin Colorectal Cancer. 2013 Mar;12(1):8-14. doi: 10.1016/j.clcc.2012.09.003. Epub 2012 Oct 26. Review.

PMID:
23102544
4.

Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.

Saif MW, Garcon MC, Rodriguez G, Rodriguez T.

In Vivo. 2013 Jul-Aug;27(4):531-4. Erratum in: In Vivo. 2013 Sep-Oct;27(5):668.

PMID:
23812226
5.

Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.

Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R, Dörken B.

Br J Cancer. 1998 Mar;77(6):973-7.

6.

Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.

Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N.

J Cancer Res Clin Oncol. 2008 Jan;134(1):75-82. Epub 2007 Jul 17.

PMID:
17636329
7.

Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.

Decoster L, Neyns B, Akouaouach H, Fontaine C, Schallier D, De Grève JL.

Anticancer Res. 2004 May-Jun;24(3b):2037-40.

8.
10.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
12.

Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.

Jensen SA, Sørensen JB.

Cancer Chemother Pharmacol. 2006 Oct;58(4):487-93. Epub 2006 Jan 18.

PMID:
16418875
13.

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele Bianco A, El-Serafi M, Bedenne L, Paillot B, Mini E, Sanches E, Welch J, Collette L, Praet M, Wils J.

Eur J Cancer. 2008 Oct;44(15):2204-11. doi: 10.1016/j.ejca.2008.07.002. Epub 2008 Aug 15.

PMID:
18707870
14.

Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.

Osterlund P, Orpana A, Elomaa I, Repo H, Joensuu H.

Br J Cancer. 2002 Sep 9;87(6):591-9.

15.

Fluoropyrimidine-associated cardiotoxicity: revisited.

Saif MW, Shah MM, Shah AR.

Expert Opin Drug Saf. 2009 Mar;8(2):191-202. doi: 10.1517/14740330902733961 . Review.

PMID:
19309247
16.

[Cardiotoxicity induced by 5-fluorouracil or capecitabine].

Jensen SA, Baeksgaard L, Petersen LN, Reiter L, Sørensen JB.

Ugeskr Laeger. 2010 Jan 4;172(1):48-51. Danish.

PMID:
20056096
17.

Acute cardiotoxicity during capecitabine treatment: a case report.

Bertolini A, Flumanò M, Fusco O, Muffatti A, Scarinci A, Pontiggia G, Scopelliti M.

Tumori. 2001 May-Jun;87(3):200-6. Review.

PMID:
11504378
18.

Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.

Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A.

Expert Opin Drug Saf. 2014 Jan;13(1):113-29. doi: 10.1517/14740338.2014.845167. Epub 2013 Oct 5. Review.

PMID:
24093908
19.

Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.

Molteni LP, Rampinelli I, Cergnul M, Scaglietti U, Paino AM, Noonan DM, Bucci EO, Gottardi O, Albini A.

Breast J. 2010 Sep-Oct;16 Suppl 1:S45-8. doi: 10.1111/j.1524-4741.2010.01004.x.

PMID:
21050310
20.

Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.

Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL.

Cancer Treat Rev. 2013 Dec;39(8):974-84. doi: 10.1016/j.ctrv.2013.03.005. Epub 2013 Apr 10. Review.

PMID:
23582737

Supplemental Content

Support Center